POET Technologies' Photonics Story Faces a Reality Check as Stock Sits 37% Below Its $21 Fundraising Price

The narrative surrounding POET Technologies has rarely been more contradictory. On one side sits a freshly filled $400 million institutional capital raise, a marquee supply deal with Lumilens, and a planned tenfold capacity expansion in wafer production and optical engine assembly. On the other, a stock that closed on May 28 at $13.26 — a full 36.9% south of the $21-per-unit issue price from just ten days earlier. The gap between promise and price has rarely yawned wider.

Nearly 21 million shares changed hands that day. The market capitalization hovered around $2.03 billion. No new company filing emerged in the preceding 48 hours to explain the move, but the damage had already been done: the close on May 14 stood at $20.57, and an intraday peak of $20.81 had been wiped away. The premium that accompanied the May 18 funding announcement has evaporated, leaving the stock trading below both the issue price and the level at which warrants — exercisable at $26.25 over three years — were attached.

A Revenue Beat Overshadowed by a Doubled Loss

The selloff has its roots in the quarterly report released in mid-May. POET posted first-quarter revenue of $503,389, a 201.9% year-over-year jump that easily beat the analyst consensus of $250,000. But the headline was overshadowed by a net loss of $12.34 million, translating to a loss per share of $0.08 — twice the $0.04 that Wall Street had penciled in.

The loss figure, which widened sequentially from the prior quarter’s $341,202 in revenue and a smaller deficit, has become the central concern for institutional investors. The company’s ability to convert its technological story — photonic integrated circuits, optical engines, and high-speed interconnects for AI data centers — into recurring revenue remains unproven at scale.

Should investors sell immediately? Or is it worth buying POET Technologies?

Lumilens and the Capacity Buildout

Management points to the Lumilens supply agreement as the commercial linchpin. The initial purchase order totals $50 million, with a five-year framework that could push the cumulative value beyond $500 million. POET also holds options on more than 22 million shares priced at $8.25 over nine years, a structure that aligns the customer’s incentives with the stock’s long-term appreciation.

The $400 million fundraising is earmarked for manufacturing infrastructure, R&D, the light-source business, and working capital. CEO Suresh Venkatesan has tied the capital to a planned tenfold capacity increase in wafer production and optical engine assembly by 2027. The company now employs more than 115 people globally and operates 20,000 square feet of assembly space in Malaysia, with expanded lab and office facilities in Singapore.

Yet the operational buildup has yet to translate into sustainable profits. The net loss in Q1 underscores the heavy spending required to move from pilot production to volume shipments. The market is now measuring the story not by the size of the raise, but by the speed at which orders become revenue.

Short Sellers, a Class Action, and a Divided Crowd

The bear case has multiple pillars. Short interest stands at roughly 20% of the float. Analyst recommendations lean sell, with price targets clustered near $8.00. A class-action lawsuit is gathering momentum, with the lead-plaintiff deadline set for June 29. The allegations center on company disclosures made during the April crash, when the stock plunged 45% in a single session on reports that Marvell Technology had canceled all orders from Celestial AI — a key customer in the photonics ecosystem.

That April 27 rout erased $7.15 in a day and amplified concerns about customer concentration and execution risk. Prominent commentator Jim Cramer has voiced skepticism, citing dilution history and the lack of stability. His view contrasts sharply with the retail enthusiasm on Reddit, where bulls fixate on the Lumilens deal and the Malaysian production capacity as catalysts for recovery.

POET Technologies at a turning point? This analysis reveals what investors need to know now.

The Next Test

POET now faces a delicate balancing act. The $400 million provides a runway, but it also raises the bar. The second quarter has been a roller coaster: a 45% collapse, a capital raise at $21, and a subsequent slide below that level. High-frequency trading and retail speculation have amplified the volatility.

The fundamental question remains unchanged from the day the financing closed: Can POET transform technology demonstrations and prototype orders into a repeatable revenue stream? The answer will determine whether the stock eventually reclaims its fundraising price or continues to trade as a discount to its own capital.

Ad

POET Technologies Stock: New Analysis - 29 May

Fresh POET Technologies information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated POET Technologies analysis...

en | CA73044W3021 | POET | boerse | 69443300 |